The Effectiveness of Gout ’Treat-to-Target’ Booklet in Improving Gout Outcome

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220317054316N2

Enrollment

Registered

2022-06-03

Start date

2022-08-01

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout. Gout

Interventions

Intervention 1: Intervention group: 1.Gout ‘Treat-to-Target’ Booklet will be given to monitor the outcome of the study on the gout outcome and the standard medication care for gout. Intervention 2: Co

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: adult age 18 and more, Fullfill ACR/EULAR 2015 gout criteria, patient referred to Rheumatology clinic UiTM for the management of =1 of the condition such as inter-critical gout with frequent flare (=4 flare a year) and/or; polyarticular gout and/or; chronic advanced gout (with or without tophi) and/or; SUA level > 480 ?mol/L. Able to speak and read in Malay agree to participate and sign written consent

Exclusion criteria

Exclusion criteria: patients with contraindications to Allopurinol and Febuxostat (severe heart failure, end stage renal failure and severe hepatic impairment of Child’s C liver cirrhocis); patients with dementia

Design outcomes

Primary

Measure	Time frame
1. gout flare. Timepoint: before intervention, week-8, week-16. Method of measurement: number of episodes, duration and severity (Likert scale 1 - 10 with 10 most severe).;Laboratory: serum uric acid, creatinine, liver function test. Timepoint: Baseline, week-8, week-16. Method of measurement: blood taking and using machine in the laboratory.;Disability index. Timepoint: baseline, week-8, week-16. Method of measurement: Questionnaire: Health Assessment Questionnaire Disability Index (HAQ-DI).	—

Measure

Time frame

1. gout flare. Timepoint: before intervention, week-8, week-16. Method of measurement: number of episodes, duration and severity (Likert scale 1 - 10 with 10 most severe).;Laboratory: serum uric acid, creatinine, liver function test. Timepoint: Baseline, week-8, week-16. Method of measurement: blood taking and using machine in the laboratory.;Disability index. Timepoint: baseline, week-8, week-16. Method of measurement: Questionnaire: Health Assessment Questionnaire Disability Index (HAQ-DI).

—

Countries

Malaysia

Contacts

Public ContactHazlyna Baharuddin

Universiti Teknologi MARA

hazlyna@uitm.edu.my+60 12-617 3021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026